Scalper1 News
The FDA approved Bristol-Myers Squibb’s (BMY) drug Opdivo for non-squamous lung cancer Friday afternoon, almost three months ahead of its deadline, boosting Bristol-Myers stock. Opdivo had already been approved for melanoma and for squamous-cell lung cancer, which represents a minority of lung-cancer patients. The FDA had until Jan. 2 to decide whether to allow it for patients with the more common non-squamous variety that had worsened after one Scalper1 News
Scalper1 News